Aug 31, 2023, 19:04
Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.
Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently tweeted:
“Brand new paper alert from our group Ph2 CLIA with or without sorafenib for upfront AML therapy led by Tapan Kadia, Hagop Kantarjian, Gautam Borthakur, Naval Daver, Naveen Pemmaraju, Nitin Jain and Musa Yilmaz.”
For the article click here.
Source: Naveen Pemmaraju/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14